The Canadian unit of French-drugmaker Sanofi Aventis said that its dupilumab injection (Dupixent) has been approved as an add-on maintenance treatment in patients aged six to 11 years with severe asthma with a type 2 / eosinophilic phenotype or oral corticosteroid-dependent asthma. The company said that the approval comes after the success of the VOYAGE phase 3 trial which enrolled 408 children aged six to 11 years with uncontrolled moderate- to severe asthma. The company pointed out that Dupixent was first approved in Canada in 2017 for the treatment of adults with atopic dermatitis.